CADL: Aglatimagene nears BLA submission after positive phase III data, targeting focused launch and key accounts
Two viral immunotherapies are advancing, with aglatimagene showing strong phase III results in prostate cancer and a BLA submission planned by year-end. The launch will focus on top accounts, with positive payer feedback and integration into radiation workflows. Key near-term catalysts include biom…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.